Mary Ford-Naill, MBA’s Post

Nanopharmaceuticals are revolutionizing healthcare with their precision and efficiency. Here’s a look at the key players driving this innovative market: 🔹 Merck: Leading the way in nanotechnology research and development. #Merck 🔹 Pfizer: Pioneering new frontiers in drug delivery systems. #Pfizer 🔹 Novartis: Innovating targeted therapies with nanomedicine. #Novartis 🔹 Abbott: Enhancing drug formulations with cutting-edge nanotech. #Abbott 🔹 GlaxoSmithKline: Advancing nanopharmaceutical applications for better patient outcomes. #GlaxoSmithKline 🔹 Roche: Developing nanomedicines that push the boundaries of conventional treatments. #Roche 🔹 Sanofi: Integrating nanotechnology to create next-gen pharmaceuticals. #Sanofi 🔹 Eli Lilly: Leading in the development of innovative nanodrugs. #EliLilly 🔹 AstraZeneca: Pioneering targeted cancer treatments with nanotechnology. #AstraZeneca 🔹 Johnson & Johnson: Utilizing nanotechnology for advanced therapeutic solutions. #JohnsonAndJohnson 🔹 Celgene: Innovating cancer treatments with nanomedicine. #Celgene 🔹 Novavax: Developing cutting-edge vaccines with nanotechnology. #Novavax 🔹 Stryker: Transforming drug delivery systems through nanotech. #Stryker 🔹 Gilead Sciences: Pushing the envelope in antiviral nanopharmaceuticals. #GileadSciences 🔹 OSI Pharmaceuticals: Advancing targeted nanotherapies for oncology. #OSIPharmaceuticals 🔹 Kadmon Pharmaceuticals: Innovating treatment approaches with nanomedicine. #KadmonPharmaceuticals 🔹 Samyang Biopharm: Integrating nanotechnology into therapeutic developments. #SamyangBiopharm 🔹 Mitsubishi Pharma: Leveraging nanotech for novel drug formulations. #MitsubishiPharma 🔹 Kaken Pharmaceutical: Pioneering nano-based drug delivery systems. #KakenPharmaceutical 🔹 Selecta Biosciences: Leading the charge in targeted nanomedicine. #SelectaBiosciences 🔹 Par Pharmaceutical: Revolutionizing drug delivery with nanotechnology. #ParPharmaceutical 🔹 Cerulean Pharma: Innovating nanoparticle-based therapies. #CeruleanPharma 🔹 Navidea Biopharmaceuticals: Enhancing diagnostic and therapeutic solutions with nanotech. #NavideaBiopharmaceuticals 🔹 Lummy: Leading in the development of advanced nanopharmaceuticals. #Lummy Embrace the future of healthcare with nanopharmaceuticals! 🧬🔬 #Nanopharmaceuticals #Nanomedicine #HealthcareInnovation #MedicalResearch #PharmaTech #Biotech #DrugDelivery #PrecisionMedicine #FutureOfMedicine #HealthcareTransformation Read Report @ https://lnkd.in/gyexAKpt

🎉 Big News in Biotech! 🧬 Pfizer, a global pharmaceutical leader, has just inked a monumental 15-year lease for their oncology division in San Diego, marking the region's largest biotech transaction in over a year. This move into the Torrey View office and lab campus by Pfizer emphasizes the ongoing expansion and innovation in cancer therapy research. 🏢💡 As part of Breakthrough Properties’ development, this 230,000-square-foot lease brings the campus to full occupancy before its completion, showcasing the vibrant future of biotech in San Diego, the nation's third-largest biotech hub. 🌟 This lease symbolizes a significant boost in the biotech sector, amidst a time when life science deals are seeking momentum. It reflects the industry's shift towards major research and development efforts in areas like cancer, diabetes, and more. 📈🔬 San Diego continues to attract global pharmaceutical giants, fostering advancements and potentially life-saving therapies. Let's celebrate this leap forward in biotech innovation and the promising developments it heralds for healthcare. 🎗️ For more details on this, check out the full article here: https://lnkd.in/gQMqwkTe (Note: Article is behind a Members only login). . . . . #AJGeorgeResimercial #CommercialRealEstateSanDiego #ResimercialRealEstate #ResimercialRealtor #RealEstateTransactions #Biotech #Pfizer #HealthcareIndusty #HealthcareInnovation #SanDiegoBiotech

Strategy Collaboration    BioNTech and Autolus Therapeutics have announced a strategic collaboration to advance their autologous CAR-T programs toward commercialization. The collaboration includes a license and option agreement and a securities purchase agreement. BioNTech will invest $200 million in Autolus' American Depositary Shares and will have the right to appoint a director to Autolus' board. BioNTech will make a cash payment of $50 million and receive certain rights in exchange, including royalties on net sales of Autolus' obe-cel therapy. Autolus will retain full rights to develop and commercialize obe-cel. BioNTech plans to expand its BNT211 program into trials for multiple cancer indications using Autolus' manufacturing facilities. The collaboration also grants BioNTech access to Autolus' cell targeting tools for the development of in vivo cell therapy and antibody-drug conjugate candidates.    💡With GlobalData's #patent module, we offer specialized expertise in the #pharmaceutical industry. Our unique blend of #data, #insights, and #analytics ensures a tailored approach, delivering comprehensive answers to specific patent-related inquiries. 🧠💼 Empower your understanding with our precise and insightful deliverables – because innovation deserves nothing less! 💪 #healthcarerevolution #CardiovascularInnovation #PatentExcellence    To learn more about our Patent capabilities or to have a chat, just drop us an 📧email at [email protected] or☎contact us here>>> https://lnkd.in/deGad__f and we will get in touch!    #patents #drugs #biontech #autolus

Insilico Medicine, a biotech startup, has reached a major milestone! They've developed a novel pharmaceutical compound using AI that is currently in Phase II clinical trials. This achievement underscores the remarkable potential of AI in drug discovery. Traditionally, the journey to this stage is long and costly, but AI is revolutionizing the pace of progress. This breakthrough heralds promising implications for the medical landscape, facilitating the discovery of diverse treatment options for various diseases. #Biotech #Innovation #AI https://lnkd.in/gEkJi9-5

I've been OOO for a few weeks and there's been plenty of deals over the last few weeks across Biotech and Medtech. Here are some highlights I found. Have a great week ahead. 📢 Cardurion Pharmaceuticals was made flush in 2021 thanks to a $300 million investment. Now, the biotech is looking to challenge the statin-dominated cardiovascular status quo with a $260 million series B fundraising round. 📢The digital health developer Huma announced that it has raised $80 million to help carry it through the ongoing rollout of its cloud-based platform for managing patients regardless of their specific disease. 📢Lantheus is expanding its holdings of PET imaging agents for Alzheimer’s disease, with the acquisition of Meilleur Technologies. The deal grants Lantheus exclusive worldwide rights to Meilleur’s radiopharmaceutical diagnostic that highlights beta amyloid plaques in the brain 📢Element Biosciences nets $277M ahead of new sequencer launch. 📢With a new go-ahead from antitrust regulators in the U.K., Thermo Fisher Scientific is on its way to closing its $3.1 billion deal for Olink, the Swedish developer of protein analyzers, antibody tests and research services. 📢SK Biopharmaceuticals inks $572M deal for Full-Life prospect, advancing push to become Asia’s radiopharma leader 📢Sionna Therapeutics has quickly found a use for some of its $182 million series C haul, inking a deal with AbbVie to add three clinical-phase candidates to its burgeoning pipeline of cystic fibrosis prospects. 📢GE Healthcare to buy AI software from Intelligent Ultrasound for $51M 📢Artiva Biotherapeutics has upsized its IPO to $167 million as the allogeneic natural killer (NK) cell therapy prepares to list on the Nasdaq. 📢Sotio has struck a deal to fuse bispecifics with its antibody-drug conjugate (ADC) capabilities, agreeing to pay Biocytogen up to $325.5 million in upfront and milestone fees for rights to targeting molecules. Newton Colmore is a specialist recruiter, dedicated to the medical devices, biotech, and drug discovery markets, globally. We help our clients find the experts they need to develop and commercialise novel devices, technologies, and therapeutics. #biotech #medtech #medicaldevices #drugdiscovery

📰 Great news! Bright Peak Therapeutics has successfully secured investment of 90 million US dollars after closing a Series C financing round. According to a press release, Johnson & Johnson Innovation – JJDC led the financing round for the biotechnology company, which is based at our Switzerland Innovation Park Basel Area - Main Campus and in San Diego, in the US State of California. With the proceeds from this financing round, the company is aiming to advance BPT567, a first-in-class PD1-IL18 immunoconjugate, into a Phase 1/2a clinical trial in the second half of 2024. Preclinical models have demonstrated that single agent BPT567 possesses a highly targeted biological and therapeutic effect with potent antitumor activity by blocking the PD-1 receptor, while at the same time directing the potent pro-inflammatory effects of IL-18 specifically to effector T cells in the tumor microenvironment. Read more right here: https://lnkd.in/ecmJkkAv 💬 “We are now well positioned to bring much needed innovation to the field of anti-PD-1 immune-checkpoint inhibition and look forward to advancing our lead program into the clinic later this year across multiple tumor types”, comments Fred Wiklund, Chief Executive Officer of Bright Peak, in the press release, before adding: “This capital raise provides financial flexibility to bring new therapeutic modalities to patients with cancer and we’re delighted to have attracted the confidence of a global pharmaceutical company and strong support from such a distinguished syndicate of leading life sciences investors”. 👉 Meet our residents right here: https://lnkd.in/eSKdb6SD senn.com #innovation #lifesciences #success #biotech

Insilico Medicine, a biotech startup, has reached a major milestone! They've developed a novel pharmaceutical compound using AI that is currently in Phase II clinical trials. This achievement underscores the remarkable potential of AI in drug discovery. Traditionally, the journey to this stage is long and costly, but AI is revolutionizing the pace of progress. This breakthrough heralds promising implications for the medical landscape, facilitating the discovery of diverse treatment options for various diseases. #Biotech #Innovation #AI https://lnkd.in/eVvVicFs

✨ Dive into the Future of Medicine with Coya Therapeutics, Inc.! 🚀 Watch CEO Howard Berman, Ph.D. reveal the secrets behind their game-changing exosome engineering technology in an exclusive interview on "Innovators with Jane King." 🧬🎥 Don't miss out – click on the link below 👇 to witness the revolution and join the conversation on reshaping healthcare! #BiotechAdvancements #MedicalInnovation #CoyaTherapeutics

That should better stick: molecular glue is one of the most exciting possible futures in #Biopharma and #Biotech Although I had already covered this topic almost 6 months ago (Link ➡ https://lnkd.in/dQiwuETe), recent events shed more lights on the growing interest by Big Pharma in the field, as well as the inherent challenges associated with next generations innovations. Growing interest by Big Pharma... Last week, Takeda signed a collaboration of up to $1.2bn with molecular glue young biotech company Degron Therapeutics (Link ➡https://lnkd.in/dFhiBZGe). Interestingly, the collaboration goes beyond oncology and extends into inflammation and neuroscience. This reminds us of the Roche and Monte Rosa Therapeutics collaboration of up to $2bn to co-develop pre-clinical programs in oncology and neuroscience, which was announced about 6 months ago (Link ➡ https://lnkd.in/dMnf5tcD). However, Monte Rosa Therapeutics has continued to be active in the BD&L and financing space. As Takeda was in the final stages of inking a deal with Degron Therapeutics, Monte Rosa Therapeutics announced a $100M follow-on offering on Nasdaq (Ticker $GLUE), in a mix of common shares and pre-funded warrants (a sign that the IPO market remains difficult right now). (Link ➡https://lnkd.in/d9s3aHZt) Some commentators have been questionning the move... With a treasure chest of c. $200M and a cash runway going well into year 2027, why would Monte Rosa Therapeutics raise an additional $100M when its share price is close to an all-time low? This brings us to the inherent challenge associated with such a disruptive innovation. As competition heats up and Big Pharma get more and more into the field, the investments required to stay in the lead will only grow wider. In that context, the definition of a cash runway is a fleeting and dangerous one, for corporate executives and investors alike. #Biotech #lifesciences #capitalmarkets #businessdevelopment #communication